Bioeksma - Company finances
|
EUR
|
2018
From: 2018-01-01
To: 2018-12-31
|
2019
From: 2019-01-01
To: 2019-12-31
|
2020
From: 2020-01-01
To: 2020-12-31
|
2021
From: 2021-01-01
To: 2021-12-31
|
2022
From: 2022-01-01
To: 2022-12-31
|
2023
From: 2023-01-01
To: 2023-12-31
|
2024
From: 2024-01-01
To: 2024-12-31
|
2025
From: 2025-01-01
To: 2025-12-31
|
|---|---|---|---|---|---|---|---|---|
|
Financial data
|
||||||||
| Sales revenue | 3,215,499 | 4,369,335 | 3,561,305 | 3,967,558 | 4,079,719 | 3,903,033 | 3,738,296 | 3,820,289 |
| Profit before tax | 102,368 | 141,649 | 129,630 | 250,543 | 83,040 | 69,552 | 90,316 | 89,599 |
| Net profit | 87,949 | 115,388 | 105,903 | 208,595 | 65,829 | 55,805 | 77,304 | 71,861 |
| Equity | 977,027 | 1,092,415 | 1,098,318 | 1,006,913 | 572,742 | 628,547 | 705,851 | 677,984 |
| Liabilities | 439,273 | 572,164 | 678,993 | 755,277 | 682,227 | 797,046 | 522,501 | 394,118 |
| Non-current assets | 307,335 | 418,318 | 431,728 | 402,494 | 379,383 | 263,176 | 241,441 | 209,027 |
| Current assets | 1,105,433 | 1,244,013 | 1,345,797 | 1,358,685 | 872,436 | 1,166,164 | 991,192 | 874,975 |
| Total assets | 1,412,768 | 1,662,331 | 1,777,525 | 1,761,179 | 1,251,819 | 1,429,340 | 1,232,633 | 1,084,002 |
|
Taxes paid
|
||||||||
| STI taxes | - | - | - | - | - | 571,524 | 691,441 | 635,169 |
| Social insurance contributions | - | - | - | - | - | 119,491 | 122,734 | 130,991 |
|
Financial indicators
|
||||||||
| Revenue change y/y | +4.9% | +35.9% | -18.5% | +11.4% | +2.8% | -4.3% | -4.2% | +2.2% |
| ROA Return on Assets (ROA). The ratio of net profit to assets. Indicates the company's efficiency. | 6.2% | 6.9% | 6.0% | 11.8% | 5.3% | 3.9% | 6.3% | 6.6% |
| ROE Return on equity. The ratio of net profit to equity. Shows the return to shareholders. | 9.0% | 10.6% | 9.6% | 20.7% | 11.5% | 8.9% | 11.0% | 10.6% |
| Profit margin Net profit margin. Shows the overall profitability of the company. | 2.7% | 2.6% | 3.0% | 5.3% | 1.6% | 1.4% | 2.1% | 1.9% |
| EBT% EBT (Earnings Before Taxes) to revenue ratio. Shows the overall profitability of the company. | 3.2% | 3.2% | 3.6% | 6.3% | 2.0% | 1.8% | 2.4% | 2.3% |
| Liabilities/Equity The debt-to-equity ratio shows the company's capital structure. | 0.4 | 0.5 | 0.6 | 0.8 | 1.2 | 1.3 | 0.7 | 0.6 |
| Revenue per employee Ratio of revenue to the average annual number of employees. Indicates company efficiency. | 147,275 | 192,059 | 197,850 | 204,337 | 195,046 | 234,182 | 222,077 | 224,723 |
Sales revenue
See Scoris data in Google Search
Mark Scoris as a favorite source. One click, no registration.
Bioeksma - Social security debts
| From | To | Debt, € |
|---|---|---|
| 2021-12-30 | 2022-01-02 | 0.01 |
Bioeksma - VMI tax arrears
| From | To | Overdue, € |
|---|---|---|
| 2026-05-18 | 2026-05-18 | 22.0 |
| 2024-12-31 | 2024-12-31 | 17.6 |
| 2024-12-30 | 2024-12-30 | 5937.6 |
| 2024-12-29 | 2024-12-29 | 17.6 |
| 2024-12-28 | 2024-12-28 | 4.8 |
| 2024-12-20 | 2024-12-27 | 5924.8 |
| 2024-12-19 | 2024-12-19 | 5920.0 |
VMI debt information has been collected since 2024-10-07. Debts for older periods will not be displayed.
Analysis of the company's financial position
This description was generated by artificial intelligence.
Report if inaccurate.
Bioeksma, UAB (code 300096612) is a Private Limited Liability Company operating in the wholesale of other machinery and equipment. In 2025, the company generated revenue of €3.82M, up 2.2% year on year, after €3.74M in 2024 and €3.90M in 2023. Net profit amounted to €71.9K in 2025, compared with €77.3K in 2024 and €55.8K in 2023, indicating a generally positive but somewhat fluctuating profit trajectory. The profit margin was 1.9% in 2025, versus 2.1% in 2024 and 1.4% in 2023. At year-end 2025, total assets stood at €1.08M, with equity of €678.0K and liabilities of €394.1K. The equity ratio was 62.5% and debt-to-equity was 0.58, showing a relatively solid balance sheet structure. Return on equity was 10.6% and return on assets 6.6%. Asset turnover reached 3.52x, supported by revenue per employee of €224.7K and profit per employee of €4.2K. Over the last three years, revenue remained broadly stable while profitability improved from 2023 levels.